Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

King of Prussia, Pennsylvania 19406


Purpose:

Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).


Study summary:

Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.


Criteria:

- Children ages 2-17 years with fever and neutropenia. - The expected duration of neutropenia should be 10 days and due to cytotoxic chemotherapy or aplastic anemia.


NCT ID:

NCT00056381


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

King of Prussia, Pennsylvania 19406
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.